Lipid-based nanoparticle technology has developed from chemical drug carrier into an efficient multifunctional siRNA tumor targeting delivery system. In this review, we start with an overview of the lipid-based nanomedicine history and the two classes of lipidic vectors for DNA or siRNA delivery. Then we discuss the features of lipid-based nanomedicine that lead to effective tumor targeting and the principles behind. We also discuss nanoparticle surface modification, classes of tumor targeting ligands, and other state-of-the-art strategies for enhancing endosome release primarily focused on lipid-based systems. At the end, we show that multifunctional self-assembled lipid-based nanoparticles could also be versatile delivery vehicles for can...
siRNA therapeutics has developed rapidly and already there are clinical trials ongoing or planned; h...
Since their inception in the 1980s, oligonucleotide-based (ON-based) therapeutics have been recogniz...
The clinical success of therapeutics of small interfering RNA (siRNA) is still hindered by its deliv...
Lipid-based nanoparticle technology has developed from chemical drug carrier into an efficient multi...
Nanoparticles represent particularly attractive delivery systems for small interfering RNA (siRNA) a...
RNAi (RNA interference)-based technology is emerging as a versatile tool which has been widely utili...
Nanoparticles represent particularly attractive delivery systems for small interfering RNA (siRNA) a...
Macromolecules such as nucleic acids and inorganic nanoparticles require a delivery vector to capit...
The growing knowledge on the mechanisms of gene silencing and gene regulation by non-coding RNAs (nc...
Copyright: © 2012 Fatih Uckun, et al. This is an OpenAccess article distributed under the terms of ...
Small interfering RNAs (siRNAs) indicate the unprecedented versatility in silencing disease-causing ...
Successfully employing therapeutic nucleic acids, such as small interfering RNA (siRNA), requires ch...
Since their inception in the 1980s, oligonucleotide-based (ON-based) therapeutics have been recogniz...
Since their inception in the 1980s, oligonucleotide-based (ON-based) therapeutics have been recogniz...
With the discovery of RNA interference technology, small-interfering RNA (siRNA) has emerged as new ...
siRNA therapeutics has developed rapidly and already there are clinical trials ongoing or planned; h...
Since their inception in the 1980s, oligonucleotide-based (ON-based) therapeutics have been recogniz...
The clinical success of therapeutics of small interfering RNA (siRNA) is still hindered by its deliv...
Lipid-based nanoparticle technology has developed from chemical drug carrier into an efficient multi...
Nanoparticles represent particularly attractive delivery systems for small interfering RNA (siRNA) a...
RNAi (RNA interference)-based technology is emerging as a versatile tool which has been widely utili...
Nanoparticles represent particularly attractive delivery systems for small interfering RNA (siRNA) a...
Macromolecules such as nucleic acids and inorganic nanoparticles require a delivery vector to capit...
The growing knowledge on the mechanisms of gene silencing and gene regulation by non-coding RNAs (nc...
Copyright: © 2012 Fatih Uckun, et al. This is an OpenAccess article distributed under the terms of ...
Small interfering RNAs (siRNAs) indicate the unprecedented versatility in silencing disease-causing ...
Successfully employing therapeutic nucleic acids, such as small interfering RNA (siRNA), requires ch...
Since their inception in the 1980s, oligonucleotide-based (ON-based) therapeutics have been recogniz...
Since their inception in the 1980s, oligonucleotide-based (ON-based) therapeutics have been recogniz...
With the discovery of RNA interference technology, small-interfering RNA (siRNA) has emerged as new ...
siRNA therapeutics has developed rapidly and already there are clinical trials ongoing or planned; h...
Since their inception in the 1980s, oligonucleotide-based (ON-based) therapeutics have been recogniz...
The clinical success of therapeutics of small interfering RNA (siRNA) is still hindered by its deliv...